天麻素胶囊联合洛美利嗪治疗血管神经性偏头痛的临床研究

目的探讨天麻素胶囊联合洛美利嗪胶囊治疗血管神经性偏头痛的临床疗效。方法选取2016年3月—2018年3月在中国人民解放军联勤保障部队第九八三医院治疗的血管神经性偏头痛患者82例,随机分为对照组(41例)和治疗组(41例)。对照组口服盐酸洛美利嗪胶囊,5mg/次,根据病情适量增减,每日剂量不可超过20mg,2次/d;治疗组在对照组基础上口服天麻素胶囊,100 mg/次,3次/d。两组均治疗8周。观察两组患者临床疗效,同时比较治疗前后两组患者临床症状改善、SF-36和VAS评分及血清学指标和脑血流情况。结果治疗后,对照组和治疗组临床有效率分别为78.05%和95.12%,两组比较差异具有统计学意义(P0.05)。治疗后,两组头痛发作次数、头痛持续时间均显著降低(P0.05),且治疗组头痛发作次数和头痛持续时间明显低于对照组(P0.05)。治疗后,两组SF-36评分显著升高(P0.05),VAS评分显著降低(P0.05),且治疗组SF-36和VAS评分明显好于对照组(P0.05)。治疗后,两组血清超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)、高脂蛋白a(LPA)、血管内皮生长因子(VEGF)、P物质(SP)水平及椎动脉(VA)、基底动脉(BA)、大脑前动脉(ACA)、中动脉(MCA)、后动脉(PCA)的平均血流速度均显著降低(P0.05),且治疗组上述指标明显低于对照组(P0.05)。结论天麻素胶囊联合盐酸洛美利嗪胶囊治疗血管神经性偏头痛可有效改善患者临床症状,改善脑血流速度,提高患者生活质量,具有一定的临床推广应用价值。

Clinical study on Gastrodin Capsules combined with lomeflozine in treatment of vasculoneurous migraine

Objective Effect of Salvianolic Acid for Injection on expression of serum Soluble Intercellular Adhesion Molecule-1 (s ICAM-1) and Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) in patients with acute cerebral infarction. Methods Tatolly 126 patients with acute cerebral infarction were randomly divided into observation and control group. The control group was treated with routine therapy and antiplatelet therapy:oral aspirin, 100 mg per day, supplemented by other symptomatic supportive treatment. The observation group was treated with salvianolic acid 100 mg for injection, diluted with 250 mL saline, intravenously dripped once a day for 14 days. Enzyme-linked immunosorbent assay was used to examine the expression of sICAM-1 and sVCAM-1 in the serum of the two groups. Results There was no significant difference in the levels of sICAM-1 and sVCAM-1 between the two groups before treatment. The levels of sICAM-1 and sVCAM-1 in the serum of observation groups were significantly lower than those before treatment (P<0.05). The levels of sICAM-1 and sVCAM-1 in the serum of observation group were significantly lower compared with control group (P<0.05). Conclusions Salvianolic Acid for Injection has a clear effect on the levels of sICAM-1 and sVCAM-1 in the serum of patients with acute cerebral infarction.